Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405412 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL12861211 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL75490 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL256757 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL1154281 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL3510056 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL2812490 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL974709 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL13171860 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA | |
| SCHEMBL974708 | 1.00 | PKM (0.37) | PKMHSD11B1HSD11B2EPHX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | disclosed |
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2012059932-A1 | 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| US-7968601-B2 | Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| US-7968601-B2 | Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | LINDERS JOANNES T M | 2008-04-24 | — | — | US | disclosed |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | LINDERS JOANNES T M | 2008-04-24 | — | — | US | disclosed |
| US-7332524-B2 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| US-7332524-B2 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | PKM 2041/4885HSD11B1 2/4885HSD11B2 9/4885 |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | DHCR7, HSD3B2, HSD3B1 | PKM 4843/4885HSD11B1 5/4885HSD11B2 8/4885 |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HSD11B1, HSD17B11, HSD3B1 | PKM 3026/4885HSD11B1 1/4885HSD11B2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.